TABLE 1.
Comparison of cumulative incidence of bladder recurrence and progression at 1, 2, 3, 5, and 10 years after initial TURBT in patients with primary NMIBC
| Patterns of progression | 1‐year follow‐up | 2‐year follow‐up | 3‐year follow‐up | 5‐year follow‐up | 10‐year follow‐up | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WL | PDD | Incidence rate ratio (Clopper–Pearson CI) | Exact P value | WL | PDD | Incidence rate ratio (Clopper–Pearson CI) | Exact P value | WL | PDD | Incidence rate ratio (Clopper–Pearson CI) | Exact P value | WL | PDD | Incidence rate ratio (Clopper–Pearson CI) | Exact P value | WL | PDD | Incidence rate ratio (Clopper–Pearson CI) | Exact P value | |
| Bladder recurrence | 81 | 59 | 0.77 (0.54–1.09) | 0.15 | 143 | 92 | 0.76 (0.58–0.99) | 0.047 | 175 | 103 | 0.81 (0.63–1.04) | 0.094 | 207 | 113 | 0.90 (0.71–1.14) | 0.42 | 222 | 114 | 0.95 (0.75–1.20) | 0.66 |
| Conventionally defined PFS | 1 | 1 | 1.06 (0.01–83.1) | 0.74 | 6 | 3 | 0.59 (0.10–2.8) | 0.34 | 7 | 5 | 0.98 (0.25–3.6) | 0.61 | 7 | 5 | 1.18 (0.30–4.33) | 0.50 | 7 | 5 | 1.32 (0.33–4.84) | 0.42 |
| IBCG‐defined PFS | 17 | 8 | 0.50 (0.19–1.2) | 0.07 | 33 | 12 | 0.43 (0.20–0.86) | 0.007 | 42 | 15 | 0.49 (0.25–0.90) | 0.01 | 43 | 16 | 0.62 (0.32–1.12) | 0.06 | 50 | 16 | 0.59 (0.31–1.06) | 0.04 |
| Stage‐up | ||||||||||||||||||||
| Ta to Tis | 3 | 2 | 0.71 (0.06–6.2) | 0.53 | 6 | 2 | 0.39 (0.04–2.2) | 0.21 | 10 | 2 | 0.27 (0.03–1.29) | 0.06 | 10 | 3 | 0.50 (0.09–1.93) | 0.22 | 13 | 3 | 0.43 (0.08–1.55) | 0.13 |
| Ta to T1 | 10 | 3 | 0.32 (0.06–1.2) | 0.06 | 12 | 2 | 0.20 (0.02–0.89) | 0.02 | 15 | 3 | 0.27 (0.05–0.97) | 0.02 | 15 | 3 | 0.33 (0.06–1.17) | 0.05 | 17 | 3 | 0.33 (0.06–1.13) | 0.04 |
| Tis to T1 | 0 | 0 | ‐ | ‐ | 2 | 0 | ‐ | ‐ | 3 | 0 | ‐ | ‐ | 3 | 0 | ‐ | ‐ | 3 | 0 | ‐ | ‐ |
| Ta to MIBC | 0 | 0 | ‐ | ‐ | 2 | 0 | ‐ | ‐ | 2 | 2 | 1.37 (0.10–18.9) | 0.56 | 2 | 2 | 1.65 (0.11–22.8) | 0.48 | 2 | 2 | 1.85 (0.13–25.5) | 0.44 |
| Tis to MIBC | 0 | 0 | ‐ | ‐ | 1 | 0 | ‐ | ‐ | 1 | 0 | ‐ | ‐ | 1 | 0 | ‐ | ‐ | 1 | 0 | ‐ | ‐ |
| T1 to MIBC | 1 | 1 | 1.06 (0.01–83.1) | 0.74 | 3 | 3 | 1.18 (0.16–8.8) | 0.57 | 4 | 3 | 1.03 (0.15–6.1) | 0.63 | 4 | 3 | 1.24 (0.18–7.33) | 0.53 | 4 | 3 | 1.39 (0.20–8.20) | 0.47 |
| Grade‐up | ||||||||||||||||||||
| LG to HG (including CIS) | 6 | 4 | 0.71 (0.15–3.0) | 0.41 | 12 | 7 | 0.69 (0.23–1.9) | 0.29 | 15 | 7 | 0.64 (0.22–1.67) | 0.22 | 16 | 7 | 0.72 (0.25–1.86) | 0.31 | 21 | 7 | 0.62 (0.22–1.50) | 0.18 |
Abbreviations: CI, confidence interval; CIS, carcinoma in situ; LG, low grade; HG, high grade; MIBC, muscle‐invasive bladder cancer; TURBT, transurethral resection of the bladder tumour; OR, odds ratio; PDD, photodynamic diagnosis; PFS, progression‐free survival; WL, white‐light.